NYVAC-HIV-PT1

NYVAC-HIV-PT1 is an investigational prophylactic HIV vaccine candidate based on the NYVAC vector platform. It is a DNA vaccine designed to induce immune responses against HIV by expressing the HIV envelope glycoprotein gp140, targeting the virus's entry mechanism. The vaccine aims to stimulate both humoral and cellular immunity, particularly focusing on generating antibodies against key regions of the HIV envelope such as V1/V2, which are associated with protection from infection. NYVAC-HIV-PT1 has been evaluated in early-phase clinical trials for safety and immunogenicity, often in combination with other vaccines or adjuvants[2][3][5]. The primary indication is prevention of HIV infection.